bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $126.64 and last traded at $126.64, with a volume of 204 shares. The stock had previously closed at $120.85.
bioMérieux Stock Performance
The company has a debt-to-equity ratio of 0.10, a current ratio of 2.21 and a quick ratio of 1.20. The company’s fifty day moving average is $115.49 and its two-hundred day moving average is $112.78.
bioMérieux Company Profile
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Articles
- Five stocks we like better than bioMérieux
- Investing In Preferred Stock vs. Common Stock
- How to Protect Your Portfolio When Inflation Is Rising
- What is a support level?
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.
